Intranasal ketamine for chronic cancer-related pain in the outpatient setting: a double-edged sword
Intranasal ketamine may reduce opioid requirements in cancer-related pain, but adverse effects can limit tolerability. Future research should identify high-risk patients and develop risk mitigation strategies.
Authors
- Ali John Zarrabi (ORCID: https://orcid.org/0000-0002-0079-2250)
- Justine W. Welsh (ORCID: https://orcid.org/0000-0001-6418-744X)
- Vinita Singh (ORCID: https://orcid.org/0000-0002-8103-1401)
- A. Levine
- Joseph Nalbone (ORCID: https://orcid.org/0009-0006-4231-4392)
Institutions
- Emory University (US)
Publication Details
- Journal
- Pain Management
- Published
- 2025-12-09
- DOI
- https://doi.org/10.1080/17581869.2025.2599730
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 0.00